08.05.2014 Views

Introduction - Uppsala Monitoring Centre

Introduction - Uppsala Monitoring Centre

Introduction - Uppsala Monitoring Centre

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

2. ‘We were forced to work against deadlines of 60 and 180 days<br />

to prevent the automatic approval of the new drug.’ (In 1940<br />

there was only one medical officer working on new drugs<br />

which increased to two in 1950) (Larrick, 1965).<br />

3. ‘There was no provision requiring regular record keeping and<br />

reporting of clinical and other experiences with new drugs.’<br />

4. ‘We could not remove a new drug from the market unless we<br />

could prove that it was unsafe; it was not enough to show that<br />

new developments had drawn the question of its safety sharply<br />

into issue.’<br />

5. ‘There were inadequate controls over the distribution and use<br />

of investigational drugs, as the thalidomide episode showed.’<br />

[Richardson-Merrell distributed 2,528,412 thalidomide tablets<br />

to 1,267 physicians for some 20, 000 patients in the USA<br />

(Sjöstrom & Nilsson, 1972). Over 2,151 patients were given<br />

them in clinical trials. There were at least 7 cases of<br />

phocomelia (Mellin & Katzenstein, 1962)].<br />

6. ‘Prescription drug advertising, at an estimated expenditure of a<br />

quarter-of a- billion dollars per year - $1,000 for each physician<br />

in the United States–was virtually unregulated.’<br />

7. ‘Trade names were being used without proper relationship to<br />

generic names, with resulting confusion to the profession.’<br />

8. ‘The quality of “old drugs” was not assured, as it was with the<br />

“new drugs.” Only five of the classes of antibiotic drugs used to<br />

treat life-threatening infections were subject to routine batch<br />

testing and certification by our laboratories.’<br />

9. ‘And factory inspection authority was so limited as to seriously<br />

handicap our operations.’ (Larrick, 1965).<br />

Geiling and Cannon proposed that the necessary information for<br />

drugs to be supplied by pharmaceutical companies in their New Drug<br />

Applications (NDA):<br />

Chemical composition<br />

Acute toxicity studies in two species<br />

Chronic toxicity studies with different doses in different species<br />

Observation of the animals<br />

Pathologic examination of animals<br />

Studies in animals with experimental lesions<br />

Studies on the absorption and elimination of the chemical<br />

Study of interactions<br />

Knowledge of idiosyncrasies and untoward reactions (Geiling<br />

& Cannon, 1938).

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!